Articles with public access mandates - Imane El DikaLearn more
Not available anywhere: 1
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma
D Cowzer, JB White, JF Chou, PJ Chen, TH Kim, DN Khalil, IH El Dika, ...
JCO Precision Oncology 7, e2300272, 2023
Mandates: US National Institutes of Health
Available somewhere: 25
PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer
A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ...
New England Journal of Medicine 386 (25), 2363-2376, 2022
Mandates: US National Institutes of Health
Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies
JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ...
Clinical Cancer Research 25 (7), 2116-2126, 2019
Mandates: US National Institutes of Health
Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention
MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ...
Clinical Cancer Research 24 (17), 4154-4161, 2018
Mandates: US National Institutes of Health
Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection
W Park, J Chen, JF Chou, AM Varghese, KH Yu, W Wong, M Capanu, ...
Clinical Cancer Research 26 (13), 3239-3247, 2020
Mandates: US National Institutes of Health
Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial
GK Abou-Alfa, Q Shi, JJ Knox, A Kaubisch, D Niedzwiecki, J Posey, ...
JAMA oncology 5 (11), 1582-1588, 2019
Mandates: US National Institutes of Health
An open‐label, multicenter, phase I, dose escalation study with phase II expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of …
I El Dika, HY Lim, WP Yong, CC Lin, JH Yoon, M Modiano, B Freilich, ...
The oncologist 24 (6), 747-e218, 2019
Mandates: US National Institutes of Health
Immune checkpoint inhibitors for hepatocellular carcinoma
I El Dika, DN Khalil, GK Abou‐Alfa
Cancer 125 (19), 3312-3319, 2019
Mandates: US National Institutes of Health
Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings
H Maynard, ZK Stadler, MF Berger, DB Solit, M Ly, MA Lowery, ...
Cancer 126 (9), 1995-2002, 2020
Mandates: US National Institutes of Health
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies
JJ Harding, RK Do, IE Dika, E Hollywood, K Uhlitskykh, E Valentino, ...
Cancer chemotherapy and pharmacology 82, 429-440, 2018
Mandates: US National Institutes of Health
Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers
MA Lowery, M Bradley, JF Chou, M Capanu, S Gerst, JJ Harding, IE Dika, ...
Clinical Cancer Research 25 (3), 937-945, 2019
Mandates: US National Institutes of Health
A multicenter randomized three‐arm Phase II study of (1) Everolimus,(2) Estrogen Deprivation Therapy (EDT) with Leuprolide+ Letrozole, and (3) Everolimus+ EDT in patients with …
I El Dika, RJ Mayer, AP Venook, M Capanu, MP LaQuaglia, R Kobos, ...
The oncologist 25 (11), 925-e1603, 2020
Mandates: US National Institutes of Health
Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with …
MR Weiser, JF Chou, A Keshinro, WC Chapman, PS Bauer, MG Mutch, ...
JAMA Network Open 4 (11), e2133457-e2133457, 2021
Mandates: US National Institutes of Health
Hepatocellular carcinoma, novel therapies on the horizon
I El Dika, I Makki, GK Abou-Alfa
Chinese clinical oncology 10 (1), 12, 2021
Mandates: US National Institutes of Health
A phase Ib, open‐label study of dalantercept, an activin receptor‐like kinase 1 ligand trap, plus sorafenib in advanced hepatocellular carcinoma
GK Abou‐Alfa, RA Miksad, MA Tejani, S Williamson, ME Gutierrez, ...
The Oncologist 24 (2), 161-e70, 2019
Mandates: US National Institutes of Health
Phase Ib study of enzalutamide with or without sorafenib in patients with advanced hepatocellular carcinoma
JJ Harding, RK Kelley, B Tan, M Capanu, GK Do, J Shia, JF Chou, ...
The Oncologist 25 (12), e1825-e1836, 2020
Mandates: US National Institutes of Health
Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies
M Vyas, C Firat, JF Hechtman, MR Weiser, R Yaeger, C Vanderbilt, ...
Familial cancer 20, 201-213, 2021
Mandates: US National Institutes of Health
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
I El Dika, M Capanu, JF Chou, JJ Harding, M Ly, AD Hrabovsky, RKG Do, ...
Cancer Medicine 9 (20), 7453-7459, 2020
Mandates: US National Institutes of Health
Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention
NA Giraldo, E Drill, BA Satravada, IE Dika, AR Brannon, J Dermawan, ...
Clinical Cancer Research 28 (24), 5359-5367, 2022
Mandates: US National Institutes of Health
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study
JJ Harding, TS Yang, YY Chen, YH Feng, CJ Yen, CL Ho, WT Huang, ...
Cancer 127 (24), 4585-4593, 2021
Mandates: Cancer Research UK
Publication and funding information is determined automatically by a computer program